Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity
- UNCW Author/Contributor (non-UNCW co-authors, if there are any, appear on document)
- Michael Tift (Creator)
- Institution
- The University of North Carolina Wilmington (UNCW )
- Web Site: http://library.uncw.edu/
Abstract: Doxorubicin and other anthracyclines are crucial cancer treatment drugs. However, they are associated with significant cardiotoxicity, severely affecting patient care and limiting dosage and usage. Previous studies have shown that low carbon monoxide (CO) concentrations protect against doxorubicin toxicity. However, traditional methods of CO delivery pose complex challenges for daily administration, such as dosing and toxicity. To address these challenges, we developed a novel oral liquid drug product containing CO (HBI-002) that can be easily self-administered by patients with cancer undergoing doxorubicin treatment, resulting in CO being delivered through the upper gastrointestinal tract.
Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity
PDF (Portable Document Format)
8127 KB
Created on 7/12/2024
Views: 11
Additional Information
- Publication
- de Souza, R.W.A.; Voltarelli, V.; Gallo, D.; Shankar, S.; Tift, Michael S.; Young, M.; Gomperts, E.; Gomperts, A.; & Otterbein, L.E. (2024, May). Beneficial effects of oral carbon Monoxide on Doxorubicin-induced cardiotoxicity. Journal of the American Heart Association, 13 (9), Article Number e032067. DOI10.1161/JAHA.123.032067
- Language: English
- Date: 2024
- Keywords
- anthracyclines, cancer, carbon monoxide, cardiotoxicity, heme oxygenase-1